Andere talen Annexon, Inc.

Aandelen

ANNX

US03589W1027

Geschatte realtime Cboe BZX Andere beurzen 19:57:00 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,6 ^USD	+3,60%		-23,58%	+0,66%

01/04	ANNEXON, INC. : JPMorgan Chase herhaalt koopadvies voor het aandeel	ZM
27/03	ANNEXON, INC. : Wells Fargo Securities nog altijd een koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

ANNEXON REPORTS INDUCEMENT GRANTS TO NEW EMPLOYEES UNDER NASDAQ LISTING RULE 5635(4)	17/04
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)	16/04
Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference	03/04
Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference	03/04
Annexon Q4 Loss Narrows	26/03
Annexon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones	26/03
Annexon, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/03
North American Morning Briefing : Stocks Struggle After New Records	22/03
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)	18/03
North American Morning Briefing : Inflation Worries Continue to Weigh on Mood	15/03
North American Morning Briefing : Stock Futures -2-	04/03
Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference	27/02
Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference	27/02
ANNEXON REPORTS INDUCEMENT GRANT TO NEW EMPLOYEE UNDER NASDAQ LISTING RULE 5635(4)	21/02
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach	21/02
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach	21/02
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)	20/02
Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases	08/01
Annexon Insider Bought Shares Worth $1,008,000, According to a Recent SEC Filing	28/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Annexon, Inc.

Aandelen

ANNX

US03589W1027

Andere talen

Filters